Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability

Journal of Immunology

Volumn 185, Issue 3, 2010, Pages 1949-1958

  Cheung, Timothy C ^a,d   Coppieters, Ken ^c   Sanjo, Hideki ^a   Oborne, Lisa M ^a   Norris, Paula S ^a   Coddington, Amy ^b   Granger, Steven W ^b   Elewaut, Dirk ^c   Ware, Carl F ^a,e  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECOY RECEPTOR 3; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN BETA RECEPTOR; NEUTRALIZING ANTIBODY; PROTEIN LIGHT; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; HERPESVIRUS ENTRY MEDIATOR LIGAND; TNFRSF6B PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; CONTROLLED STUDY; DNA SEQUENCE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN VARIANT; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPONDYLARTHRITIS; SYNOVIOCYTE; AMINO ACID SEQUENCE; BIOLOGICAL MODEL; COCULTURE; DRUG ANTAGONISM; GENETICS; HELA CELL; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; BIOLOGICAL AVAILABILITY; COCULTURE TECHNIQUES; GENETIC VARIATION; HELA CELLS; HUMANS; INFLAMMATION MEDIATORS; MODELS, IMMUNOLOGICAL; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 77956400001     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001159     Document Type: Article

References (51)

1. Vonderheide, R. H., and C. H. June. 2003. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol. Res. 27: 341-356.
2. Appleman, L. J., and V. A. Boussiotis. 2003. T cell anergy and costimulation. Immunol. Rev. 192: 161-180.
3. Riley, J. L., and C. H. June. 2005. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105: 13-21.
4. Subudhi, S. K., M. L. Alegre, and Y. X. Fu. 2005. The balance of immune responses: costimulation verse coinhibition. J. Mol. Med. 83: 193-202.
5. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3: 609-620.
6. Ware, C. F. 2008. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol. Rev. 223: 186-201.
7. Mauri, D. N., R. Ebner, R. I. Montgomery, K. D. Kochel, T. C. Cheung, G. L. Yu, S. Ruben, M. Murphy, R. J. Eisenberg, G. H. Cohen, et al. 1998. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8: 21-30.
8. Rooney, I. A., K. D. Butrovich, A. A. Glass, S. Borboroglu, C. A. Benedict, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, and C. F. Ware. 2000. The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275: 14307-14315.
9. Bai, C., B. Connolly, M. L. Metzker, C. A. Hilliard, X. Liu, V. Sandig, A. Soderman, S. M. Galloway, Q. Liu, C. P. Austin, and C. T. Caskey. 2000. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl. Acad. Sci. USA 97: 1230-1235.
10. Yu, K. Y., B. Kwon, J. Ni, Y. Zhai, R. Ebner, and B. S. Kwon. 1999. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274: 13733-13736.
11. Cheung, T. C., M. W. Steinberg, L. M. Oborne, M. G. Macauley, S. Fukuyama, H. Sanjo, C. D'Souza, P. S. Norris, K. Pfeffer, K. M. Murphy, et al. 2009. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc. Natl. Acad. Sci. USA 106: 6244-6249.
12. Dejardin, E., N. M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, Z. W. Li, M. Karin, C. F. Ware, and D. R. Green. 2002. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17: 525-535.
13. Murphy, K. M., C. A. Nelson, and J. R. Sedý. 2006. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6: 671-681.
14. Cai, G., and G. J. Freeman. 2009. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 229: 244-258.
15. Murphy, T. L., and K. M. Murphy. 2010. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 28: 389-411.
16. Browning, J. L. 2008. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol. Rev. 223: 202-220.
17. Wang, J., J. C. Lo, A. Foster, P. Yu, H. M. Chen, Y. Wang, K. Tamada, L. Chen, and Y.-X. Fu. 2001. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J. Clin. Invest. 108: 1771-1780.
18. Shaikh, R. B., S. Santee, S. W. Granger, K. Butrovich, T. Cheung, M. Kronenberg, H. Cheroutre, and C. F. Ware. 2001. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J. Immunol. 167: 6330-6337.
19. Fava, R. A., E. Notidis, J. Hunt, V. Szanya, N. Ratcliffe, A. Ngam-Ek, A. R. De Fougerolles, A. Sprague, and J. L. Browning. 2003. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J. Immunol. 171: 115-126.
20. Kang, Y. M., S. Y. Kim, J. H. Kang, S. W. Han, E. J. Nam, H. S. Kyung, J. Y. Park, and I. S. Kim. 2007. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. Arthritis Rheum. 56: 1106-1117.
21. Edwards, J. R., S. G. Sun, R. Locklin, C. M. Shipman, I. E. Adamopoulos, N. A. Athanasou, and A. Sabokbar. 2006. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum. 54: 1451-1462.
22. Lo, J. C., Y. Wang, A. V. Tumanov, M. Bamji, Z. Yao, C. A. Reardon, G. S. Getz, and Y. X. Fu. 2007. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316: 285-288.
23. Anders, R. A., S. K. Subudhi, J. Wang, K. Pfeffer, and Y. X. Fu. 2005. Contribution of the lymphotoxin beta receptor to liver regeneration. J. Immunol. 175: 1295-1300.
24. Sedý, J. R., P. G. Spear, and C. F. Ware. 2008. Cross-regulation between herpesviruses and the TNF superfamily members. Nat. Rev. Immunol. 8: 861-873.
25. Cheung, T. C., I. R. Humphreys, K. G. Potter, P. S. Norris, H. M. Shumway, B. R. Tran, G. Patterson, R. Jean-Jacques, M. Yoon, P. G. Spear, et al. 2005. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc. Natl. Acad. Sci. USA 102: 13218-13223.
26. Lünemann, J. D., and C. Münz. 2009. EBV in MS: guilty by association? Trends Immunol. 30: 243-248.
27. Pender, M. P. 2009. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun. Rev. 8: 563-568.
28. Rist, M., C. Smith, M. J. Bell, S. R. Burrows, and R. Khanna. 2009. Crossrecognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition. Blood 114: 2244-2253.
29. Granger, S. W., K. D. Butrovich, P. Houshmand, W. R. Edwards, and C. F. Ware. 2001. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J. Immunol. 167: 5122-5128.
30. Tello-Ruiz, M. K., C. Curley, T. DelMonte, C. Giallourakis, A. Kirby, K. Miller, G. Wild, A. Cohen, D. Langelier, A. Latiano, et al. 2006. Haplotype-based association analysis of 56 functional candidate genes in the IBD6 locus on chromosome 19. Eur. J. Hum. Genet. 14: 780-790.
31. Rooney, I. A., C. A. Benedict, P. S. Norris, and C. F. Ware. 2001. Methods of study of tumor necrosis factor-related ligands in apoptosis. Methods Cell Biol. 66: 499-526.
32. Motoki, K., E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, V. Albert, M. Muto, H. Yoshida, M. Aoki, et al. 2005. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. 11: 3126-3135.
33. Rooney, I., K. Butrovich, and C. F. Ware. 2000. Expression of lymphotoxins and their receptor-Fc fusion proteins by baculovirus. Methods Enzymol. 322: 345-363.
34. Melis, L., B. Vandooren, E. Kruithof, P. Jacques, M. De Vos, H. Mielants, G. Verbruggen, F. De Keyser, and D. Elewaut. 2010. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann. Rheum. Dis. 69: 618-623.
35. Pattyn, F., F. Speleman, A. De Paepe, and J. Vandesompele. 2003. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 31: 122-123. (Pubitemid 36150349)
36. Cheung, T. C., L. M. Oborne, M. W. Steinberg, M. G. Macauley, S. Fukuyama, H. Sanjo, C. D'Souza, P. S. Norris, K. Pfeffer, K. M. Murphy, et al. 2009. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J. Immunol. 183: 7286-7296.
37. Chang, Y. C., Y. H. Chan, D. G. Jackson, and S. L. Hsieh. 2006. The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J. Immunol. 176: 173-180.
38. Castellano, R., C. Van Lint, V. Peri, E. Veithen, Y. Morel, R. Costello, D. Olive, and Y. Collette. 2002. Mechanisms regulating expression of the tumor necrosis factor-related light gene. Role of calcium-signaling pathway in the transcriptional control. J. Biol. Chem. 277: 42841-42851.
39. Kong, M., Y. Kim, and C. Lee. 2008. Promoter sequence variants of LIGHT are associated with female vascular dementia. J. Biomed. Sci. 15: 545-552.
40. Steinberg, M. W., O. Turovskaya, R. B. Shaikh, G. Kim, D. F. McCole, K. Pfeffer, K. M. Murphy, C. F. Ware, and M. Kronenberg. 2008. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J. Exp. Med. 205: 1463-1476.
41. Bamias, G., S. I. Siakavellas, K. S. Stamatelopoulos, E. Chryssochoou, C. Papamichael, and P. P. Sfikakis. 2008. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin. Immunol. 129: 249-255.
42. Hayashi, S., Y. Miura, T. Nishiyama, M. Mitani, K. Tateishi, Y. Sakai, A. Hashiramoto, M. Kurosaka, S. Shiozawa, and M. Doita. 2007. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum. 56: 1067-1075. (Pubitemid 46608631)
43. Han, B., R. Bojalil, L. M. Amezcua-Guerra, R. Springall, H. Valderrama-Carvajal, J. Wu, and H. Luo. 2008. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus. Int. Immunol. 20: 1067-1075.
44. Lee, C. S., C. Y. Hu, H. F. Tsai, C. S. Wu, S. L. Hsieh, L. C. Liu, and P. N. Hsu. 2008. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin. Exp. Immunol. 151: 383-390.
45. Sung, H. H., J. H. Juang, Y. C. Lin, C. H. Kuo, J. T. Hung, A. Chen, D. M. Chang, S. Y. Chang, S. L. Hsieh, and H. K. Sytwu. 2004. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J. Exp. Med. 199: 1143-1151.
46. Shen, H. W., S. L. Gao, Y. L. Wu, and S. Y. Peng. 2005. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J. Gastroenterol. 11: 5926-5930.
47. Wu, Y., B. Han, H. Sheng, M. Lin, P. A. Moore, J. Zhang, and J. Wu. 2003. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 105: 724-732. (Pubitemid 36687744)
48. Chen, G., and D. Luo. 2008. Expression of decoy receptor 3 in liver tissue microarrays. Natl. Med. J. India 21: 275-278.
49. Chen, C., C. Zhang, G. Zhuang, H. Luo, J. Su, P. Yin, and J. Wang. 2008. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Cancer Invest. 26: 965-974.
50. Haybaeck, J., N. Zeller, M. J. Wolf, A. Weber, U. Wagner, M. O. Kurrer, J. Bremer, G. Iezzi, R. Graf, P. A. Clavien, et al. 2009. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295-308.
51. El-Serag, H. B. 2004. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(Suppl 1): S27-S34. (Pubitemid 39423367)